Month: September 2024

Yili Reports FY2024 H1 Revenue of 59.9 Billion Yuan with 19% YoY Growth in Net Profit Attributable to the Parent Company

Written by Customer Service on September 2, 2024. Posted in Earnings Releases And Operating Results.

HOHHOT, China, Sept. 02, 2024 (GLOBE NEWSWIRE) — On August 29, Yili Group (600887.SS) released its FY2024 H1 report. During the reporting period, the company continued to solidify its industrial leadership with a total revenue of 59.915 billion yuan ($8.45 billion). With a record-high growth of 19.44% YoY in net profit attributable to the parent company totaling 7.531 billion yuan ($1.06 billion), it has set a new record amongst Asian dairy companies.A Media Snippet accompanying this announcement is available by clicking on this link. In the 2024 Global Dairy Top 20 Report published by Rabobank, Yili once again secured its place among the global top five, firmly holding onto its top leadership position in the Asian dairy industry for the 11th consecutive year. In FY2024 H1, the company’s liquid milk business recorded a...

Form 8.3 – [ECKOH PLC – 30 08 2024] – (CGWL)

Written by Customer Service on September 2, 2024. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree ECKOH PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position held/dealing...

Biopolymers Market is Expected to Grow from 17.10 billion 2023 to reach 35.60 billion in 2031 | SkyQuest Technology

Written by Customer Service on September 2, 2024. Posted in Mergers And Acquisitions.

Westford, USA, Sept. 02, 2024 (GLOBE NEWSWIRE) — Global biopolymers market was valued at USD 15.60 billion in 2022 and is poised to grow from USD 17.10 billion in 2023 to USD 35.60 billion by 2031, growing at a CAGR of 9.60% in the forecast period (2024-2031). Download a detailed overview: https://www.skyquestt.com/sample-request/biopolymers-market In recent times, the biopolymers market has experienced a dramatic surge owing to the increasing demand for PHA-based biodegradable plastics. Most of the prominent packaging and plastics manufacturing organizations are shifting towards biodegradable products as there is a rising popularity of eco-friendly packaging from end-users of various industries. Biopolymers are utilized in different types of applications like biomedical, pharmaceuticals, and food & beverage. They are also...

Form 8.3 – [KEYWORDS STUDIOS PLC – 30 08 2024] – (CGWL)

Written by Customer Service on September 2, 2024. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree KEYWORDS STUDIOS PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position...

Schouw & Co. share buy-back programme, week 35 2024

Written by Customer Service on September 2, 2024. Posted in Public Companies.

On 4 March 2024, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 13 of 1 March 2024. Under the programme, Schouw & Co. will acquire shares for up to DKK 200 million during the period 4 March 2024 to 31 December 2024. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules).Trading day No. of shares Average price Amount Accumulated until 23/8/2024 204,687 549.36 112,446,917 Monday, 26 August 2024 1,500 585.92 878,880 Tuesday, 27 August 2024 1,600 579.66 927,456 Wednesday, 28 August 2024 1,700 579.00 984,300 Thursday,...

Central Iron Ore Limited: Drilling Commences

Written by Customer Service on September 2, 2024. Posted in Public Companies.

VANCOUVER, British Columbia, Sept. 02, 2024 (GLOBE NEWSWIRE) — Central Iron Ore Limited (CIO – TSX.V) (“CIO” or “the Company”) is pleased to announce this Drilling Update. Central Iron Ore is pleased to announce that the next phase of exploration activities at the South Darlot Gold Project in Western Australia has started on the 28th of August 2024, with a total 42 Reverse Circulation (‘RC’) and 4 diamond holes scheduled to be completed over a 2 to 3 week campaign (Figure 1). Figure 1. Drilling has commenced at the South Darlot Gold Project Highlights:Drilling has commenced on 42 RC drillholes for 1,968 metres that will further positive results encountered at the satellite prospects at South Darlot and include Mermaid, Sylvia/Kyneton and Weebo (Figures 2-4). Commencing in September, 200 metres of Diamond Drilling...

Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today

Written by Customer Service on September 2, 2024. Posted in Public Companies.

Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today Oxford, UK – 2 September 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, “OXB” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, announces that Lucinda (Lucy) Crabtree Ph.D. has today joined Oxford Biomedica as Chief Financial Officer (CFO) and board member. Lucinda’s appointment was previously announced on 17 July 2024. Lucinda Crabtree was previously at MorphoSys AG where she served as CFO, leading a finance team across the US and Germany until the company’s acquisition by Novartis. Previously, she was CFO at Autolus Therapeutics, a Nasdaq listed clinical stage biopharmaceutical company. Lucinda also brings extensive experience from the investment and banking sectors, having held roles at institutions including Woodford...

Correction: Admiral Markets AS 2024 Unaudited 6 Months Financial Results

Written by Customer Service on September 2, 2024. Posted in Earnings Releases And Operating Results.

Admiral Markets AS 2024 Unaudited 6 Months Financial ResultsDespite the low volatility in the financial markets in the first half of 2024, Admiral Markets AS delivered increased trading revenues and positive EBITDA through effective cost control measures. The Company’s net trading income increased by 21% to EUR 6.9 million (6M 2023: EUR 5.7 million).The Company’s operating expenses decreased by 29% to EUR 6.8 million (6M 2023: EUR 9.6 million).EBITDA was EUR 1.2 million (6M 2023: EUR -3.0 million).Net profit was EUR 0.9 million (6M 2023: EUR -3.9 million).Admirals voluntarily decided in April 2024 to temporarily suspend the onboarding of new customers for Admirals Europe Ltd. This decision is related to Admirals Europe Ltd’s efforts to comply with and adapt to the recommendations of the CySEC...

Correction: Admirals Group AS 2024 Unaudited 6 Months Financial Results

Written by Customer Service on September 2, 2024. Posted in Earnings Releases And Operating Results.

Admirals Group AS 2024 Unaudited 6 Months Financial Results Despite the low volatility in the financial markets in the first half of 2024, Admirals Group AS delivered increased trading revenues and positive EBITDA through effective cost control measures. The Group’s net trading income increased by 4% to EUR 22.0 million (6M 2023: EUR 21.1 million). The Group’s operating expenses decreased by 9% to EUR 22.9 million (6M 2023: EUR 25.2 million). EBITDA was EUR 0.4 million (6M 2023: EUR -2.9 million). Net loss was EUR -1.2 million (6M 2023: EUR -4.8 million). Admirals voluntarily decided in April 2024 to temporarily suspend the onboarding of new customers for Admirals Europe Ltd. This decision is related to Admirals Europe Ltd’s efforts to comply with and adapt to the recommendations of the CySEC regulator and affects only...

Risk-weighted assets – exposure to real estate in Greenland

Written by Customer Service on September 2, 2024. Posted in Public Companies.

Since 1 December 2023, the Danish FSA has conducted a consultation on “The Danish FSA’s assessment of well-developed and well-established markets in the Faroe Islands and Greenland”. 29 August, the Danish FSA concluded the consultation. During the consultation period, the BANK of Greenland has not recognised any possible effect in the Bank’s risk-weighted assets in the event of a changed assessment of all or parts of the Bank’s real estate exposure. On the basis of the uncertainty resulting from the consultation, the Bank has maintained higher core capital ratio in the Bank than the Bank’s previous target of approximately 24%. In the interim report for the first half of 2024, core capital was 24.7%. On the conclusion of the consultation, it has been established that the assessment of well-developed and well-established...

Month: September 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals